Cell Research - Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma Skip to main content Thank you for visiting nature.com.

New preclinical research shows a promising drug combination that targets ovarian cancer’s survival pathways, paving the way ...

Gene set comparison analyses of gene expression signatures for the acquired chemotherapy resistance. Background: The PI3K/AKT/mTOR signaling pathway is a central network in a number of cancers, ...

Fig 1. PI3K/AKT/mTOR signaling pathway showing interacting activation and regulatory feedback loops. Adapted from Hoeffer and Klann. 35 Mammalian target of rapamycin (mTOR) is a serine-threonine ...

This finding suggests these cancers may have been driven by tamoxifen-induced activation of the phosphatidylinositol 3-kinase (PI3K) pathway, researchers concluded. Data derived from Kubler K, et ...

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the ...

Phosphatidylinositol 3-kinase (PI3K) is involved in multiple cell processes, including insulin signaling, cell growth, immunity, and brain development. It is activated in a wide variety of cancers ...

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

In short, preclinical models may not necessarily permit the detection of context-specific activation of PI3K (or other effectors) by mutant KRAS.

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the ...